This study will compare tenecteplase, a newer clot-busting drug, with alteplase, which is currently the routine treatment used in hospitals.
About 80% strokes are caused by a blocked blood vessel. One third of these patients have a blockage of a large blood vessel in the neck or brain known as large artery occlusion stroke (LAOS).
Researchers at University College London say that stroke care needs to be centralised in large specialist units in a radical shake-up of hospitals.
The University of Central Lancashire’s (UCLan) Professor of Stroke Care has been awarded the DBE in the Queen’s New Year’s Honours List. Professor Caroline Watkins, who is the only stroke care professor in the UK, was honoured for her services to stroke and nursing care.
Released today, the Scottish Stroke Improvement Programme 2016 Annual National Report includes data from the Scottish Stroke Care Audit. It describes the quality of stroke care in each acute hospital in Scotland, grouped by Health Board, during 2015, and measures each hospital against Scottish Stroke Care Standards (2013).
A panel of independent experts has decided that alteplase, a clot-busting drug often used to treat strokes is safe and effective under current guidelines.
After a stroke some people have difficulty swallowing (dysphagia). This can cause a serious chest infection known as Stroke Associated Pneumonia (SAP). Published in the journal Cerebrovascular Diseases, a new systematic review of the evidence sheds light on the issue.
The Stroke Association's response to the latest National Clinical Guideline for Stroke (2016) produced by the Intercollegiate Stroke Working Party of the Royal College of Physicians of London.
At present it is not clear how best to organise NHS services so that patients can benefit from thrombectomy for stroke. The Institute of Heath Services, Newcastle University, has produced an online survey to understand the preferences of stroke survivors, their carers and the public on the future of stroke thrombectomy service organisation in the UK.
Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2) - TSA BHF 2015/01